Protocol Ledger

NCT03941860 · Phase III · COMPLETED

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Interventional Phase III clinical trial protocol NCT03941860 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-02-16 Enrollment: 1 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03941860
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03941860
Protocol FieldVerified Registry Value
NCT IdentifierNCT03941860
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment1 participants (ACTUAL)
Registered Start Date2022-02-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI